| Aug 8 |
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates
|
| Aug 5 |
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
|
| Jul 31 |
SAB Biotherapeutics names Lucy To as CFO
|
| Jul 31 |
SAB BIO Appoints Lucy To as Chief Financial Officer
|
| Jun 20 |
SAB Biotherapeutics rebrands as SAB BIO; reaffirms full-year outlook
|
| Jun 20 |
SAb Biotherapeutics Rebrands as SAB BIO
|
| Jun 18 |
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
|
| May 30 |
SAB Biotherapeutics announces departure of CFO
|
| May 30 |
SAB Biotherapeutics Announces Departure of Chief Financial Officer
|
| May 21 |
SAB Biotherapeutics GAAP EPS of -$0.43 beats by $0.60
|
